Bill Text: IA SF307 | 2023-2024 | 90th General Assembly | Introduced
Bill Title: A bill for an act relating to step therapy protocols and interchangeable biosimilars.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2023-02-23 - Subcommittee recommends indefinite postponement. []. [SF307 Detail]
Download: Iowa-2023-SF307-Introduced.html
Senate
File
307
-
Introduced
SENATE
FILE
307
BY
ALONS
A
BILL
FOR
An
Act
relating
to
step
therapy
protocols
and
interchangeable
1
biosimilars.
2
BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
3
TLSB
2200XS
(4)
90
ko/rn
S.F.
307
Section
1.
Section
514F.7,
subsection
1,
Code
2023,
is
1
amended
by
adding
the
following
new
paragraphs:
2
NEW
PARAGRAPH
.
0b.
“Biological
product”
means
the
same
as
3
defined
in
section
155A.3.
4
NEW
PARAGRAPH
.
00b.
“Biosimilar”
means
the
same
as
defined
5
in
42
U.S.C.
§262.
6
NEW
PARAGRAPH
.
0i.
“Interchangeable”
means
the
same
as
7
defined
in
42
U.S.C.
§262.
8
NEW
PARAGRAPH
.
00i.
“Interchangeable
biological
product”
9
means
the
same
as
defined
in
section
155A.3.
10
Sec.
2.
Section
514F.7,
subsection
4,
paragraph
a,
Code
11
2023,
is
amended
to
read
as
follows:
12
a.
Prevent
a
health
carrier,
health
benefit
plan,
or
13
utilization
review
organization
from
requiring
a
covered
person
14
to
try
a
prescription
drug
with
the
same
generic
name
and
15
demonstrated
bioavailability
,
or
a
biological
product
that
16
is
an
interchangeable
biological
product
pursuant
to
section
17
155A.32
,
or
an
interchangeable
biosimilar
prior
to
providing
18
coverage
for
the
equivalent
branded
prescription
drug.
19
EXPLANATION
20
The
inclusion
of
this
explanation
does
not
constitute
agreement
with
21
the
explanation’s
substance
by
the
members
of
the
general
assembly.
22
This
bill
relates
to
step
therapy
protocols
and
23
interchangeable
biosimilars.
24
Under
current
law,
a
health
carrier,
health
benefit
plan,
or
25
utilization
review
organization
may
require
a
covered
person
26
(person)
to
try
a
prescription
drug
(drug)
with
the
same
27
generic
name
and
demonstrated
bioavailability,
or
a
biological
28
product
that
is
an
interchangeable
biological
product,
prior
to
29
providing
coverage
for
an
equivalent
branded
drug.
The
bill
30
allows
a
health
carrier,
health
benefit
plan,
or
utilization
31
review
organization
to
also
require
a
person
to
try
an
32
interchangeable
biosimilar
prior
to
providing
coverage
for
an
33
equivalent
branded
drug.
“Biosimilar”
and
“interchangeable”
34
are
defined
in
the
bill.
35
-1-
LSB
2200XS
(4)
90
ko/rn
1/
1
